Investing.com -- Compass Therapeutics, Inc. (NASDAQ:CMPX) shares fell 80% Monday after the company announced results from its COMPANION-002 Phase 2/3 study of tovecimig in biliary tract cancer ...

Investing.com -- Compass Therapeutics (NASDAQ:CMPX) shares tumbled 80% Monday following mixed results from its Phase II/III COMPANION-002 trial evaluating tovecimig combined with paclitaxel in ...

Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...

Combat Providence Analysis System' (hereinafter '#Compass'), a real-time battle game co-developed by its Japanese subsidiary ...

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares fell 23% to $3.85 in premarket ...

Third Avenue Small-Cap Value Fund initiated a position in Compass, Inc. following its merger with Anywhere. Read the full ...

Nos últimos meses, mudanças nos preços do Jeep Compass chamaram atenção. O veículo, que por anos manteve valores elevados, ...

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

Heartland Christian School will host Compass Career Day on Tuesday, featuring representatives from multiple businesses and ...

Compass Mining, a leading provider of Bitcoin mining infrastructure and services, today announced its new partnership with SpiderPool, the world's ...

Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...

Compass, Zillow, and eXp rolled out coming soon programs with different rules on exclusivity, MLS limits and lead routing.